Previous studies in our laboratory have shown that IGFBP-2 is a novel regulator of the ERα, and that FASN and ERα overexpression in hyperglycaemic conditions contributes to chemo-resistance in breast cancer cells. Here, ESR1 is linked to breast carcinoma.